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A
 
BSTRACT
 
Considerable evidence supports the role of dendritic
cells (DC) in the pathogenesis of allergic diseases.
Dendritic cells, as the most potent antigen-presenting
cells (APC) for the induction of primary immune
response to antigen, are deeply involved in the dif-
ferentiation of naïve T cells into Th2 cells, thereby
developing the development of allergic sensitization.
After sensitization, DC may also function as a major
APC to control the activation and clonal expansion of
memory Th2 cells. In addition, DC are able to produce
chemokines to recruit Th2 cells into inflammatory sites,
indicating DC are important agents in various phases
of allergic inflammation. Recently, we have demon-
strated that monocyte chemotactic protein-1 not only
regulates the homing of DC, but also modulates DC
function. The present paper reviews the role of DC in
the regulation of the Th2 response in allergic diseases
and discusses the possibility of a new therapeutic
strategy targeting chemokine-mediated regulation of
DC function.
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I
 
NTRODUCTION
 
Numerous experimental and clinical studies support
the concept that CD4
 
+
 
 T cells that produce a Th2
cytokine profile (e.g. interleukin (IL)-4, IL-5, IL-13 and
IL-9) are responsible for pathophysiological manifesta-
tions of allergic diseases.
 
1
 
 Antigen-derived stimulation
from antigen-presenting cells (APC) is essential for the
generation and activation of antigen-specific Th2 cells.
However, the role of APC in the pathogenesis of allergic
disease has been disregarded. Dendritic cells (DC) are
the most potent APC: their unique ability to stimulate a
primary T cell response places them in a pivotal role with
regard to immune responses.
 
2
 
 Precursors of DC migrate
from peripheral blood into peripheral tissues and are
distributed as immature DC. The immature DC take up
antigens and move to the draining lymph nodes while
maturing into efficient APC by processing antigen to form
an antigen–peptide–major histocompatibility complex
(MHC) complex and upregulating costimulatory mole-
cules. Matured DC present antigen-derived peptide to
naïve T cells in the T cell zone of the draining lymph
nodes. Thereby, DC initiate acquired immune responses.
In human nasal mucosa, CD1a
 
+
 
 DC and CD123
 
high
 
plasmacytoid DC are identified in the epithelia and
lamina propria, respectively.
 
3
 
 Accumulation of DC into
the nasal mucosa of patients with allergic rhinitis occurs
after topical allergen challenge. In contrast, human
leukocyte antigen (HLA)-DR
 
+
 
CD1a
 
+
 
 myeloid DC, but not
CD123
 
high
 
 plasmacytoid DC, are identified in human
bronchial mucosa.
 
4
 
 The frequency of DC in the bronchial
mucosa of asthmatic patients is higher than in healthy
individuals. Moreover, the frequency increases after aller-
gen exposure. Inhaled corticosteroid treatment dimin-
ishes the number of DC in the airways of patients with
asthma and allergic rhinitis, suggesting that DC play an
important role in the allergic reaction of the airways.
 
4,5
D
 
ENDRITIC
 
 
 
CELLS
 
 
 
ORCHESTRATE
 
 
 
ANTIGEN
 
-
 
SENSITIZATION
 
: I
 
MMUNOGENIC
 
 
 
OR
 
 
 
TOLEROGENIC
 
 
 
RESPONSE
 
Soluble protein antigen delivered through an intact
mucosal surface does not provoke strong immune
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responses under normal circumstances. Instead, it
induces a state of antigen-specific hyporesponsiveness.
 
6
 
In the absence of ongoing inflammation and an immune
response, DC located in peripheral tissues, including
the bronchial mucosa, are immature, lack costimulatory
molecules and present antigen inefficiently.
 
2
 
 Naïve
T cells are thought to fail to respond or become anergic
to the antigen when the immature DC present antigen
to naïve T cells because of the requirement of both an
antigen-derived signal and costimulatory signals to acti-
vate naïve T cells. This failure leads to peripheral toler-
ance.
 
7
 
 In contrast, the antigen-specific T cell response
and the subsequent sensitization to antigen occur either
under a state of coincident respiratory virus infection
or in the presence of locally overexpressed granulocyte–
macrophage colony stimulating factor (GM-CSF) or
when antigen is delivered with lipopolysaccharide
(LPS).
 
8,9
 
 It is presumed that signals from pathogens and
pro-inflammatory cytokines, often referred to as ‘danger
signals’, induce the maturation of DC into efficient APC,
resulting in an immunogenic response.
 
2,10
 
 Therefore, the
maturation state of DC, which depends on the nature of
antigen and the local environment, determines whether
sensitization to antigens is induced or not.
Akbari 
 
et al
 
.
 
11
 
 reported that tolerogenic DC and
IL-10-producing regulatory T cells (Tr1 cells) in bronchial
lymph nodes play an important role in the tolerance
induced by antigen inhalation. The tolerogenic DC that
produce large amounts of IL-10 and express inducible
costimulator (ICOS) ligand regulate Tr1 differentiation.
In contrast, DC in mesenteric lymph nodes have been
shown to produce transforming growth factor (TGF)-
 
β
 
and to induce Th3 cells,
 
11
 
 which are essential players in
oral tolerance and produce mainly TGF-
 
β
 
. These obser-
vations support the concept that certain types of DC
actively induce tolerance as tolerogenic DC.
 
I
 
NSTRUCTIVE
 
 
 
ROLE
 
 
 
OF
 
 DC 
 
IN
 
 
 
THE
 
 
 
DIFFERENTIATION
 
 
 
OF
 
 
 
NAÏVE
 
 T 
 
CELLS
 
 
 
INTO
 
 
T
 
H
 
1/T
 
H
 
2
 
Several factors regulate Th subset development, includ-
ing: (i) the nature and intensity of T cell receptor-
mediated signals; (ii) the cytokine and humoral milieu in
which naive T cells are primed; (iii) the strength and
nature of costimulatory signals; (iv) the type of APC; and
(v) the ratio of T cell to APC.
 
12,13
 
 The integration of these
signals according to the genetic background of T cells
dictates Th subset differentiation (Fig. 1). Among all
factors, IL-12 and IL-4 play critical roles in the differenti-
ation of naïve T cells into Th1 and Th2 effectors,
respectively. In addition to the role of primary APC for
naïve T cells, DC are a main source of IL-12. Thus, they
are able to induce differentiation of Th1 cells. It has
been demonstrated that naïve T cells are themselves
capable of producing IL-4 and that endogenous IL-4
leads to Th2 differentiation under the shortage of a Th1
driving force by IL-12.
 
13
 
 Moreover, costimulatory signals
delivered through CD86 and OX40 ligand (OX40L) and
cytokines secreted by DC, such as IL-6 and monocyte
chemotactic protein (MCP)-1, reinforce endogenous IL-4
production of naïve T cells, resulting in commitment to
Th2 cells.
 
14–16
 
 Therefore, DC are inferred to be deeply
involved in the differentiation into Th2 cells.
Initially, the lineage of DC was proven to determine
differentiation of Th subsets (e.g. myeloid DC induce Th1
and plasmacytoid DC induce Th2).
 
2
 
 However, DC have
functional plasticity, by which DC show different effector
functions, including cytokine-producing ability and
surface costimulatory molecule expression, depending
on the conditions during their initial activation as sentinel
cells.
 
17
 
 Myeloid DC matured in the presence of prosta-
glandin (PG) E
 
2
 
 acquired the capability of inducing Th2
cells by decreasing IL-12-producing ability and enhanc-
ing OX40L expression, whereas DC matured in the pres-
ence of interferon (IFN)-
 
γ
 
 produce high amounts of IL-12
upon subsequent engagement of naïve T cells, leading to
the development of Th1 cells. Moreover, upon microbial
infection, different microbial compounds polarize the
maturation of human myeloid DC into stably committed
Th1 cell-promoting (DC1) or Th2 cell-promoting effector
DC (DC2); they polarize Th cells via different mecha-
nisms.
 
18
 
 Notably, heterogeneity exists within DC1 and
DC2 subsets in terms of the expression and use of Th-
polarizing molecules, even though the DC1 and DC2
induce similar Th1 and Th2 cell subsets, respectively.
Within DC2, the DC primed with soluble egg antigens of
 
Schistosoma mansoni
 
 use OX40L to promote the devel-
opment of Th2 cells, whereas DC primed with cholera
toxin or PGE
 
2
 
 promote Th2 cells via one or more uniden-
tified soluble factores.
 
18
 
More recently, human myeloid DC stimulated with
thymic stromal lymphopoietin (TSLP) 
 
in vitro
 
 acquired an
ability to induce helper T cells producing IL-5 and IL-13.
Keratinocytes in the skin lesions of atopic dermatitis
expressed TSLP; its mRNA is detected in bronchial epithe-
lia and fibroblasts.
 
19
 
 It is possible that TSLP expressed by
bronchial epithelia of asthma patients allows DC to
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induce differentiation of effector T cells involved in aller-
gic inflammation.
 
E
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CELLS
 
Harris 
 
et al
 
.
 
20
 
 reported that, after adoptive transfer of
 
in vitro
 
-activated T cells, effector memory T cells that
migrated into the airway produced substantial cytokines
upon antigen challenge, but were incapable of prolifer-
ating or migrating back to the lymph nodes. In contrast,
central memory T cells homing into the lymph nodes
could be stimulated by antigen to proliferate, produce
effector cytokines and migrate to peripheral tissues. The
DC are capable of capturing antigens at airways and
transferring processed antigen into the lymph nodes,
where clonal expansion of antigen-specific T cells occurs
(Fig. 2). Eosinophils also accumulate in the draining
lymph nodes during eosinophilic airway inflammation
and are capable of inducing some proliferation in
effector T cells, but not as vigorous as that induced by
DC.
 
21
 
 These findings suggest that clonal expansion of
Th2 cells is controlled mainly by DC. An allergic
inflammation model has revealed that a unique subset
of airway CD11c
 
+
 
CD11b
 
+
 
 DC expressing high levels of
costimulatory molecules retain and present antigen for a
prolonged period after exposure to the antigen, suggest-
ing the involvement of airway DC in chronic infiltration
of Th2 and chronic eosinophilic airway inflammation.
 
22
 
In an allergic airway inflammation model, depletion of
DC by ganciclovir treatment from antigen-sensitized thy-
midine kinase-transgenic mice led to failure to develop
eosinophilic infiltration and goblet cell hyperplasia upon
re-exposure to inhaled antigen.
 
23
 
 These results indicate
that DC are extremely important for presenting inhaled
antigen to T cells in the lung, even after sensitization to
the antigen.
Histamine affects the maturation of DC upregulating
CD86 and MHC class II expression and suppressing
IL-12 production.
 
24
 
 Freshly isolated DC from allergic
patients express Fc
 
ε
 
RI and take up antigens efficiently
through IgE immobilized on Fc
 
ε
 
RI.
 
25
 
 These data suggest
that, once antigen-specific IgE is produced, IgE-mediated
antigen uptake and histamine released from mast cells
allow DC to effectively induce differentiation of Th2 cells.
Engagement of Fc
 
ε
 
RI stimulates DC to produce IL-16,
a chemoattractant of helper T cells and eosinophils.
 
26
 
Furthermore, TSLP-activated DC produce thymus and
 
Fig. 1
 
Differentiation of Th cells
induced by dendritic cells (DC).
CpG, unmethylated CpG dinucle-
otides motif; TCR, T cell recep-
tor; Ag, antigen; IL, interleukin;
MCP-1, monocyte chemotactic
protein-1; IFN-
 
γ
 
, interferon-
 
γ
 
;
PGE
 
2
 
, prostaglandin E
 
2
 
; ICAM-1,
intercellular adhesion molecule-1;
ICOSL, inducible costimulator
ligand; OX40L, OX40 ligand.
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activation-regulated chemokine (TARC) and macrophage-
derived chemokine (MDC), which selectively attract Th2
cells.
 
19
 
 The Th2 cell-derived IL-4 and IL-13 augment
MDC production by DC.
 
27
 
 Thereby, DC are involved in
the amplification of allergic inflammation by regulating
the recruitment of Th2 cells and eosinophils into inflam-
matory sites, as well as the clonal expansion of Th2 cells.
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 OF ALLERGIC DISEASES
Because DC play important roles in several steps
of allergic inflammation (including the generation of
antigen-specific Th2 cells and amplification) and in
the maintenance of allergic inflammation, elucidating
the function of DC could be a novel therapeutic target of
allergic diseases. Some current asthma treatments puta-
tively function through their effects on DC. The regular
use of inhaled corticosteroid, which is the most effective
controller in asthma treatment, is associated with a
marked reduction in the number of CD1a+ DC in the
bronchial mucosa of asthma patients.4 The inhibitory
effect of inhaled corticosteroid on the number of DC
may occur through suppression of the production of
chemokines and cytokines that regulate the accumula-
tion and maturation of DC. Alternatively, the steroid
could induce apoptosis of immature DC in the airway
and suppress differentiation of monocytes into DC. More
recently, humanized anti-IgE therapy has been shown to
be an effective asthma treatment.28 Anti-IgE inhibits free
IgE from binding to FcεR. Thereby, it attenuates the
activation of mast cells and basophils. Because DC of
allergic patients also express functional FcεR, anti-IgE
may prevent them from producing IL-16 and taking up
antigen through FcεR, resulting in diminished accumula-
tion and activation of Th2 cells.
Molecules involved in the Th2 cell-polarizing activity
of DC depend on the nature of the antigens and the
maturing conditions.18 Studies with knockout animals
have demonstrated an important contribution of an
OX40/OX40L interaction to the development of Th2-
mediated pulmonary inflammation,29 suggesting that
OX40L is the important Th2-polarizing molecule of DC in
the pathogenesis of atopic asthma and the most efficient
therapeutic target molecule to block DC function. In a
murine model of asthma, administration of neutralizing
Fig. 2 Roles of dendritic cells (DC) during the sensitization to antigen (Ag) and subsequent allergic inflammation. IL, interleukin;
MDC, macrophage-derived chemokine; TARC, thymus and activation-regulated chemokine.
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anti-OX40L monoclonal antibody (mAb) during the
antigen-sensitization period abolished the induction of
asthmatic responses characterized by airway hyper-
sensitivity, accumulation of eosinophils, increased mucus
production and high levels of Th2 cytokines in the lung.29
However, the administration of anti-OX40L mAb during
airway challenge with antigen failed to inhibit asthmatic
responses. These results indicate that blocking of OX40L
could be an effective treatment when started prior to, but
not after, the development of asthma. Further studies are
required to confirm the clinical usefulness of OX40L
blockade because the differentiation of naïve T cells into
Th2 cells in asthma patients presumably occurs even after
manifestation of asthma symptoms.
MODULATION OF DC FUNCTION BY 
CHEMOKINES
The recruitment of DC and their precursors into periph-
eral tissues and the migration of maturating DC into
draining lymph nodes are regulated by various chemo-
kines.30 The biological activities of chemokines encom-
pass effects on the activation of immunocompetent cells
in addition to those on the recruitment of inflammatory
cells.31 Concurrent with that observation, we found that
monocyte-derived DC generated in the presence of
MCP-1 displayed a markedly reduced production
of IL-12 in response to CD40 ligand.32 Although
MCP-1 affected neither the surface phenotype nor the
T cell-stimulating activity of DC, naïve T cells stimulated
with MCP-1-primed DC produced much less IFN-γ
and favored differentiation into Th2 effector cells32
(Y Ohshima et al., unpubl. data, 2002). Neither macro-
phage inflammatory protein (MIP)-1α nor eotaxin, the
receptor of which is also expressed on monocyte-derived
DC, affected DC function. Therefore, it is conceivable
that MCP-1 modulates the differentiation of monocytes
into DC and thereby shifts the Th1/Th2 balance to Th2
(Fig. 3). More recently, monocytes expressing CCR2, a
functional receptor for MCP-1, were shown to be
recruited preferentially to inflammatory lesions and to
differentiate into DC.33 It was reported that, depending
on the state and nature of the inflammation, the attrac-
tion of DC precursors into the airway may be governed
by a different set of chemokine receptors and their
ligands; alternatively, different subsets of DC may be
recruited.34 Neutralization of MCP-1 to modulate DC
function and to inhibit the accumulation of DC into the
airway is inferred to be a feasible therapeutic strategy for
asthma because increased levels of MCP-1 have been
detected in bronchoalveolar lavage fluids and bronchial
tissue from asthma patients.35 Supporting this possibility,
it has been reported that, in murine models of asthma,
the administration of anti-MCP-1 antibodies during
allergic airway response diminishes airway hyper-
reactivity and the inflammation that is associated with a
decrease in leukotrienes and Th2-derived cytokines.36,37
In addition, viral CC chemokine inhibitor (vCCI; a
poxvirus-derived protein) and the cyclic retro-inverso
analog constructed of D-amino acids in the reverse
sequence (termed NR58-3.14.3), which are broad-
spectrum chemokine inhibitors, were shown to be highly
Fig. 3 Monocyte chemotactic
protein (MCP)-1 may influence
the differentiation and effector
function of Th2 cells by modulat-
ing the function of dendritic cells
(DC). Monocyte chemotactic
protein-1 is involved in the
recruitment of DC precursors
into inflammatory sites and in
the functional maturation of DC
in terms of Th-polarizing activity.
IL, interleukin; HEV, high endo-
thelial venules.
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effective in inhibiting allergen-induced asthma in
mice.38,39 These chemokine inhibitors may present alter-
native procedures to regulate the recruitment and
function of DC instead of neutralizing antibody.
ADJUVANT ROLE OF DC IN ANTI-ATOPY 
VACCINE
The application of counterbalance by Th1 cells or the
inhibitory effects of regulatory T cells on Th2-dominant
immune responses could be another DC-based thera-
peutic strategy because certain types of DC may be
capable of inducing Th1 and regulatory T cells.2,7
Antigen-pulsed Th1-promoting DC that become able to
produce high levels of IL-12 by in vitro modification
could be used as an anti-atopy vaccine similar to an
antitumor vaccine. Moreover, the application of various
reagents has been reported for the induction of antigen-
specific Th1 responses. Such reagents include live or
heat-killed bacteria like Bacillus Calmette–Guérin and
Lactobacillus, detoxified derivative of lipopolysaccharide
and CpG-oligodeoxynucleotide.40 Although precise
mechanisms underlying the Th1-promoting effects of
these reagents remain unclear, it is presumed that
signals through a pattern-recognition receptor, such as
Toll-like receptors, activate DC, leading to acquisition of
Th1-promoting activity. Controversy surrounds the func-
tional impairment of DC from atopic patients in terms of
IL-12 production and the expression of costimulatory
molecules.41–43 It remains to be clarified whether
antigen-pulsed DC from individuals with an atopic
predisposition show sufficient Th1-promoting activity
in vivo, but not Th2-promoting activity. In contrast, Toll-
like receptor-mediated signals may induce the secretion
of large amounts of pro-inflammatory cytokines from
DC, resulting in toxic shock. In experimental models of
asthma, adaptive transfer of allergen-specific Th1 cells
per se are reported to be capable of causing inflam-
matory responses with lung neutrophilia.44 In addition,
coadministration of allergen-specific Th1 cells enhances
infiltration of Th2 cells into the lung, engendering
deterioration of the allergic inflammatory response.44
Moreover, enhanced allergic airway inflammation and
IgE production were observed when LPS was given after
sensitization with allergen. In this context, an anti-atopy
vaccine using the Th1-promoting activity of DC seems to
have potentially harmful side-effects. Even if it was
available, its administration would preferably be com-
menced prior to the development of allergic diseases.
The term ‘regulatory T cells’ refers to those cells that
actively control or suppress the function of other cells,
generally in an inhibitory fashion.45 Currently described
candidates of regulatory T cells are Th3, Tr1,
CD4+CD25+ Tr and anergic T cells. Certain types of
regulatory T cells, termed Th3 and Tr1, preferentially
induced by intestinal and respiratory exposure to antigen,
respectively, are inferred to play an important role in the
maintenance of tolerance.45 In addition, DC are involved
in the induction of regulatory T cells.11 Adoptive transfer
of IL-10-producing pulmonary DC has been shown to
block subsequent antigen sensitization by inducing Tr1
cells.11 Furthermore, it has been reported that DC gener-
ated by treatment with a combination of steroid and
vitamin D3, cholera toxin or pertussis filamentous hemag-
glutinin are able to generate allergen-specific regulatory
T cells in vitro.46,47 The administration of antigen-pulsed
regulatory T cell-promoting DC or in vitro-generated
IL-10-producing regulatory T cells per se may help
suppress the Th2 response.
Specific mechanisms for the development and function
of regulatory T cells remain unclear. Although Th3 cells
and Tr1 cells seem to be involved primarily in regulating
gastrointestinal and respiratory diseases, respectively, it
remains uncertain which regulatory T cells effectively
control allergic diseases. It is possible that regulatory
T cells induce infectious tolerance in which T cells that are
anergized by regulatory T cells inhibit DC maturation.
Thereby, the immature DC anergize other T cells.40 Thus,
immunosuppression by regulatory T cells may engender
increased susceptibility to infection and cancer.
CONCLUDING REMARKS
Taken together, experimental evidence from animal
models and clinical evidence of the roles of DC in
allergic diseases suggest that DC are effective targets for
the development of therapeutic interventions. At least
two different DC-based therapeutic strategies exist:
(i) cellular adjuvant of anti-atopy vaccine using the APC
function of DC; and (ii) a blocking target located
upstream of the allergic inflammation cascade. Block-
ade of chemokines may be applicable to the latter
DC-based therapeutic strategy of allergic diseases.
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